Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV)
infusion once weekly to pediatric subjects with advanced solid tumors.
Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly
to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or
refractory to standard therapy or for whom standard therapy is not available. (enrollment
completed) Part 2 will be conducted in three groups of children with refractory or relapsed
pediatric solid tumors. Subjects with the following tumor types will be enrolled:
neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV
temsirolimus once weekly until disease progression or unacceptable toxicity. (recruiting)